Consistency of Spleen and Symptom Reduction Regardless of Cytopenia in Patients With Myelofibrosis Treated With Pacritinib
Clinical Lymphoma Myeloma and Leukemia · 2024
DOI: 10.1016/j.clml.2024.06.012 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024. Verfasst von Nico Gagelmann und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: n.gagelmann@uke.de. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Spleen. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CTI Biopharma.
Abstract (Originalsprache)
BACKGROUND: Pacritinib is a JAK2/IRAK1/ACVR1 inhibitor that is approved in the United States for the treatment of patients with myelofibrosis who have a platelet count 10 g/dL), with no diminution in treatment effect in patients with severe thrombocytopenia or anemia. Among 159 patients evaluable for symptoms response, improvement in total symptom score (TTS) was similar across platelet subgroups. A ≥ 50% improvement of TSS occurred more frequently in patients with baseline hemoglobin 10 g/dL. Patients with baseline hemoglobin < 8 g/dL also experienced improved hemoglobin sustained over 24 weeks, whereas subgroups with less severe anemia had stable hemoglobin levels over time. Symptom improvement as assessed using the Patient Global Impression of Change instrument was generally consistent across platelet and hemoglobin subgroups. CONCLUSION: Pacritinib demonstrates consistent efficacy in patients with MF regardless of baseline platelet and hemoglobin counts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: n.gagelmann@uke.de.
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
- Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
- Department of Medicine, O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, AL.
- Krukenberg Cancer Center, University Hospital Halle, Halle, Germany.
Förderung
- CTI Biopharma
Zitieren
APA
Gagelmann, N., Bose, P., Gupta, V., McLornan, D. P., Vachhani, P., Al-Ali, H. K., Ali, H., Treskes, P., Buckley, S., Roman-Torres, K., & Scott, B. (2024). Consistency of Spleen and Symptom Reduction Regardless of Cytopenia in Patients With Myelofibrosis Treated With Pacritinib. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2024.06.012
Vancouver
Gagelmann N, Bose P, Gupta V, McLornan DP, Vachhani P, Al-Ali HK, et al. Consistency of Spleen and Symptom Reduction Regardless of Cytopenia in Patients With Myelofibrosis Treated With Pacritinib. Clinical Lymphoma Myeloma and Leukemia. 2024. doi:10.1016/j.clml.2024.06.012
BibTeX
@article{Gagelmann2024,
author = {Gagelmann, Nico and Bose, Prithviraj and Gupta, Vikas and McLornan, Donal P and Vachhani, Pankit and Al-Ali, Haifa-Kathrin and Ali, Haris and Treskes, Philipp and Buckley, Sarah and Roman-Torres, Karisse and Scott, Bart},
title = {Consistency of Spleen and Symptom Reduction Regardless of Cytopenia in Patients With Myelofibrosis Treated With Pacritinib},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2024},
doi = {10.1016/j.clml.2024.06.012}
}
EUVIMED